anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
The air in the bedroom of study subjects in the active comparator arm was filtered by an air filtration device which processed air through a pre-filter, a high efficiency particular air (HEPA) filter and an active carbon filter. The duration of being in the active comparator arm was 2 weeks.
The invention relates to fatty acid 5-desaturase capable of catalyzing the conversion of dihomolinoleic acid to arachidic aacid. Description is made of the sequences of nucleic acids encoding 5-desaturase, the seuquences of nucleic acids which hybridize with them, DNA sctructure including 5-desaturase gene, and recombinant host microorganism or animal expressing higher levels of 5-desaturase. Methods are revealed about the fatty acid nonsaturation in 5th position and for the production of arachidic acid by expression of elevated levels of 5th desaturase. Fatty acids and fats containing them which are unsaturated by 5-desaturase produced by recombinant host microorganisms or animals are proposed. The invention also relates to pharmaceutical compositions, to compositions for baby foods or dietetic additives containing fatty acids which are unsaturated by 5-desaturase produced by recombinant host microorganism or animal. 88 claims
A system and method for providing remote healthcare. The system includes a server and a medical kit. A remote patient in need of medical care or a bystander (user) may access and use the medical kit. The remote patient and/or other user may enter data of the condition of the patient via a user interface of the medical kit. A processor of the medical kit receives data and sends the data over a wireless network to the server via communications interfaces. The processor of the medical kit than receives data including instructions for using the plurality of medical tools from the server and produces the instructions to the user via the user interface.
The aim of this study was to explore the associations between diet quality, socio-demographic measures, smoking, and weight status in a large, cross-sectional cohort of adults living in Yorkshire and Humber, UK. Data from 43, 023 participants aged over 16 years in the Yorkshire Health Survey, 2nd wave (2013-2015) were collected on diet quality, socio-demographic measures, smoking, and weight status. Diet quality was assessed using a brief, validated tool. Associations between these variables were assessed using multiple regression methods. Split-sample cross-validation was utilised to establish model portability. Observed patterns in the sample showed that the greatest substantive differences in diet quality were between females and males (3.94 points; P < 0.001) and non-smokers vs smokers (4.24 points; P < 0.001), with higher diet quality scores observed in females and non-smokers. Deprivation, employment status, age, and weight status categories were also associated with diet quality. Greater diet quality scores were observed in those with lower levels of deprivation, those engaged in sedentary occupations, older people, and those in a healthy weight category. Cross-validation procedures revealed that the model exhibited good transferability properties. Inequalities in patterns of diet quality in the cohort were consistent with those indicated by the findings of other observational studies. The findings indicate population subgroups that are at higher risk of dietary-related ill health due to poor quality diet and provide evidence for the design of targeted national policy and interventions to prevent dietary-related ill health in these groups. The findings support further research exploring inequalities in diet quality in the population.
Fish cartilage is enzymatically treated to extract proteins. Then the obtained solution is filtered and an alcohol is added to the filtrate to thereby precipitate sodium chondroitin sulfate. The sodium chondroitin sulfate thus produced is usable as a starting material for producing, for example, drugs, quasi drugs, medicinal additives, cosmetics and food additives. Fish cartilage is enzymatically treated to extract proteins. Then the obtained solution is filtered and the filtrate is dried to thereby give a material containing chondroitin sulfate. The material containing chondroitin sulfate thus produced is usable as a starting material for producing, for example, cosmetics and food additives.
The present invention relates to a medical composition which has the functions of reducing heat, purging pathogenic fire and detoxifying. The medical composition is characterized in that the medical composition is composed of the effective medicine ingredients of the weight proportion: 0.5 to 5 portions of rhubarb free anthraquinone, 1 portion of berberine or hydrochloride thereof, 2 to 5 portions of baicalin and secondary ingredients which can be accepted in pharmacy. The medical composition can be prepared into an oral taking medicinal preparation and/or an external applied medicinal preparation for use. Obvious complementation and cooperation synergism can be generated between the effective ingredients of the medical composition in the aspects of comprehensive inflammation resistance, virus resistance and heat elimination. The medical composition is obviously better than currently used like medicine, overcomes the conventional diarrhea action of rhubarb and has the good performance of diarrhea alleviation. The medical composition can be used for treating various disease symptoms by the efficiency of clearing away heat, removing poison, purging pathogenic fire, relaxing the bowel, resisting bacteria, resisting inflammation, resisting viruses, etc.
Participants will complete an 8-week, 16 session class. Each class will consist of approximately an hour of light exercise and an hour of education designed to meet the needs of a caregiving dyad with chronic pain.
PURPOSE:To prevent a by-product from being generated, to facilitate purification, and to produce lipid countaining a thiol group at a high yield by bringing lipid contng. an amino group on a hydrophilic group side and a thiolacton delivatives into reaction. CONSTITUTION:The suitable lipid contng. the amino group and the suitable thiolacton delivative are brought into react with the use of triethylamine, for example in a mixed medium consisting of chloroform and a small quantity of methanol. After the reaction, only the component is extracted. Further, it is dehydrated by unhydrous sodium salfate, the crude lipid including the thiol group can be obtained.
Those automatically identified as eligible and randomized to the MI-CARE arm are outreached by a study nurse care manager and offered the 12-month long virtual Collaborative Care program by telephone or video visits. Individuals are free to accept or decline the offer (e.g., stop/restart, not accept right away) during the 12 months after their randomization date.
OBJECTIVE: Patients undergoing intervention for acute iliofemoral deep vein thrombosis (IFDVT) with May-Thurner syndrome (MTS) typically require inpatient (IP) hospitalization for initial treatment with anticoagulation and management with pharmacomechanical thrombectomy. Direct oral anticoagulants and percutaneous mechanical thrombectomy (PMT) devices offer the opportunity for outpatient (OP) management. We describe our approach with these patients.
METHODS: Patients receiving intervention for acute IFDVT from January 2020 through October 2022 were retrospectively reviewed. Patients undergoing unilateral thrombectomy, venous angioplasty, and stenting for IFDVT with MTS comprised the study population and were divided into two groups: (1) patients admitted to the hospital and treated as IPs and (2) patients who underwent therapy as OPs. The two groups were compared regarding demographics, risk factors, procedural success, complications, and follow-up.
RESULTS: A total of 92 patients were treated for IFDVT with thrombectomy, angioplasty, and stenting of whom 58 comprised the IP group and 34 the OP group. All 92 patients underwent PMT using the Inari ClotTriever (Inari Medical), intravascular ultrasound, angioplasty, and stenting with 100% technical success. Three patients in the IP group required adjuvant thrombolysis. There was no difference in primary patency of the treated IFDVT segment at 12 months between the two groups (IP, 73.5%; OP, 86.7%; P = .21, log-rank test).
CONCLUSIONS: Patients with acute IFDVT and MTS deemed appropriate for thrombectomy and iliac revascularization can be managed with initiation of ambulatory direct oral anticoagulant therapy and subsequent return for ambulatory PMT, angioplasty, and stenting. This approach avoids the expense of IP care and allows for effective use of resources at a time when staffing and supply chain shortages have led to inefficiencies in the provision of IP care for nonemergent conditions.
AVELUMAB will be administered intravenously 10mg/kg every 2 weeks. Courses will be repeated every 14 days until progression or unacceptable toxicity. AVELUMAB will be administered as a 1-hour (-10 minutes / +20 minutes, i.e., 50-80 minutes) intravenous (i.v.) infusion. The dose of AVELUMAB will be calculated based on the weight of the subject determined on the day prior to or the day of each drug administration.
Chronic delta hepatitis is a serious form of chronic liver disease caused by infection with the hepatitis D virus (HDV), a small RNA virus that requires farnesylation of its major structural protein (HDV antigen) for replication. Based on previous and ongoing clinical trials demonstrating effectiveness against HDV, we propose to treat 26 adult patients with chronic delta hepatitis using the combination of the farnesyltransferase inhibitor (FTI) lonafarnib (LNF), the protease inhibitor ritonavir (RTV) and peginterferon lambda-1a(lambda). In this phase 2a open label study, the safety and antiviral effects of triple therapy with LNF, RTV and lambda for a period of 6 months. After dosing, all patients will be monitored for 24 weeks off therapy. Nucleos(t)ide analogue therapy will be instituted/continued during this study to prevent the possibility of hepatitis B virus (HBV) reactivation/flare for the duration of participation in this clinical trial. Patients with quantifiable HDV RNA in serum will be enrolled. At each clinic visit, patients will be questioned about side effects, symptoms and quality of life, undergo focused physical examination, and have blood drawn for complete blood counts, HDV RNA, and routine liver tests (including alanine aminotransferase (ALT), aspartate aminotransferase (AST), alkaline phosphatase, direct and total bilirubin, and albumin). At the end of the treatment, patients will be admitted to the clinical center and will undergo repeat liver biopsy and hepatic venous pressure gradient (HVPG) measurements, repeat physical examination, assessment of symptoms (using a symptom scale questionnaire), complete blood counts, routine liver tests, and hepatitis B and D viral markers. The primary therapeutic endpoint will be a decline of HDV RNA viral titer of 2 logs at the end of therapy. The primary safety endpoint will be the ability to tolerate the drugs at the prescribed dose for the full course of therapy. This clinical trial is designed as a phase 2a study assessing the antiviral activity, safety and tolerance of fixed doses of lonafarnib, ritonavir and peginterferon lambda.
The present invention relates to a compound for liver care. The compound for liver care includes: Graptopetalum paraguayense powder and Salviae Miltiorrhizae Radix et Rhizoma extract powder. The weight percentage of the Graptopetalum paraguayense powder is 70-90%. The weight percentage of the Salviae Miltiorrhizae Radix et Rhizoma extract powder is 2-15%. The compound for liver care in accordance with the present invention is advantageous in lowering AST(GOT) and ALT(GPT) caused by chemical liver damage, and increases the antioxidant capacity that is lowered due to chemical liver damage and alleviates liver tissue vacuolization and necrosis phenomenon resulted from chemical liver damage. In addition, the compound for liver care further includes Ganoderma extract powder, and the weight percentage of the Ganoderma extract powder is 2-15%.
Overweight and obesity now impact one-third of the entire adult population globally, and play a role in the development of 3 of the 4 more common causes of death. Accountability systems for obesity prevention centring on food environment policies and health system strengthening have been vital for raising awareness to the lack of progress in prevention. However, health systems have struggled to prevent and treat obesity - in part because critical food systems reforms largely lay outside the mandate of health sectors and with government agencies for agriculture, industry, infrastructure, trade and investment, and finance. In this commentary we highlight aspects of food systems that are driving poor diets and obesity, and demonstrate a powerful but largely overlooked opportunity for accountability mechanisms for obesity that better address food systems as a main driver. We draw on lessons generated in the Pacific Islands Region where they have demonstrated remarkable commitment to obesity prevention through food system reforms, and the adoption of accountability systems that bring leaders to account on these. We make recommendations for accountability mechanisms that facilitate greater cooperation of food systems sectors on obesity and NCD prevention.
A process for the preparation in homogeneous phase and in quantitative yield of 3-iminomethyl derivatives of rifamycin SV useful as antibiotic agents. Rifamycin S is reacted in an organic solvent .Iadd.with a compound .Iaddend. ##STR1## to give a solution of .[.1,3-oxazino-(5,6-c) rifamycins.]. .Iadd.an intermediate compound .Iaddend.which is treated with an organic solvent at a pH from 4 to 6. The aqueous phase is discharged and the organic phase is treated with an amine .Iadd.or hydrazine .Iaddend.under basic conditions, the desired derivatives being finally isolated from this organic phase according to usual techniques.
Participants received breast biopsy procedure training once. 1-2 weeks before the breast biopsy procedure.
BACKGROUND: Hip-spine syndrome (HSS) was first described in 1983 to describe the symptomatology resulting from concomitant lumbar degenerative stenosis and hip osteoarthritis. Numerous studies have sought to understand the underlying pathology and appropriate management of this syndrome. The purpose of this article is to review the literature for the specific imaging characteristics and the optimal surgical treatment of HSS.
METHODS: A systematic review was conducted via an electronic database search through PubMed to identify all publications related to HSS. All publications that contained data on patients who underwent surgical treatment for HSS and reported patient-reported outcome measures or radiographic data were included. Exclusion criteria consisted of publications in a language other than English, review articles, and technique articles.
RESULTS: Fifteen articles that focused on the surgical management of HSS were identified. Of these 15 articles, 8 reported radiographic outcomes, with most reporting no significant change in spinopelvic parameters before and after surgery. Thirteen articles reported clinical outcomes, with 8 of those 13 articles identifying patient-reported outcome measures to be significantly improved following surgery.
CONCLUSIONS: The data on the surgical management of HSS remains sparse. While there is some evidence that total hip arthroplasty in patients who previously underwent spinal fusion may have higher complication rates, there remains debate regarding which surgical problem to address first, the hip or the spine.
Serious, life-threatening, or fatal respiratory depression has been reported with the use of opioids, even when used as recommended. Respiratory depression, if not immediately recognized and treated, may lead to respiratory arrest and death. Management of respiratory depression may include close observation, supportive measures, and use of opioid antagonists, depending on the patient’s clinical status [see Overdosage (10)]. Carbon dioxide (CO2) retention from opioid-induced respiratory depression can exacerbate the sedating effects of opioids. 

While serious, life-threatening, or fatal respiratory depression can occur at any time during the use of oxycodone HCl extended-release tablets, the risk is greatest during the initiation of therapy or following a dosage increase. Monitor patients closely for respiratory depression, especially within the first 24 to 72 hours of initiating therapy with and following dosage increases of oxycodone HCl extended-release tablets. 

To reduce the risk of respiratory depression, proper dosing and titration of oxycodone HCl extended-release tablets are essential [see Dosage and Administration (2)]. Overestimating the oxycodone HCl extended-release tablets dosage when converting patients from another opioid product can result in a fatal overdose with the first dose. 

Accidental ingestion of even one dose of oxycodone HCl extended-release tablets, especially by children, can result in respiratory depression and death due to an overdose of oxycodone.
Proposed concepts aim to provide schemes, solutions, concepts, designs, methods and systems pertaining to the transmitting, receiving and/or communicating medical imaging data for remote real-time examination. In particular, a medical image is encoded (120) with an identifier based on at least part of metadata associated with the medical image. As the medical image and the metadata may have different transmission requirements (i.e. bandwidth, latency, loss, etc.), they are communicated through different communication channels (130, 140). In this way, the medical image and the metadata may be communicated appropriately, while the identifier enables the medical image and the metadata to be matched at a receiver.
BACKGROUND: Renin-angiotensin-aldosterone system inhibitors (RAASIs) play a crucial role in the treatment of several chronic cardiovascular conditions. Nonetheless, hyperkalemia, a frequent side effect, often leads to the discontinuation of RAASIs. The implications of hyperkalemia-driven changes in RAASI medications are poorly understood.
METHODS: Population-based, observational, retrospective cohort study. Two large healthcare databases were utilized to identify 77,089 individuals aged 55 years and older with chronic conditions who were prescribed RAASIs between 2015 and 2017 in Southern Barcelona, Spain. We assessed the interplay between serum potassium abnormalities, RAASI management, and their associations with clinical outcomes, adjusting for potential confounders including socioeconomic factors, medical conditions, and potassium levels.
RESULTS: The one-year prevalence of hyperkalemia (defined as serum potassium, K+ >5.0 mmol/L) was 17.8 %. RAASI were down-titrated in 16.1 % of these 13,673 patients with K+ levels. Factors linked to a higher likelihood of reducing/discontinuing RAASI after developing hyperkalemia included older age, impaired kidney function, higher potassium levels, and previous hospitalizations. Dose reduction/discontinuation of RAASI after developing hyperkalemia was associated with an increased risk of hospitalization (adjusted hazard ratio [HR] 1.16, 95 % confidence interval [CI] 1.10-1.21) and with increased mortality (HR 1.60, 95 % CI 1.56-1.84).
CONCLUSION: In this large, observational study, hyperkalemia was linked to a greater likelihood of discontinuing RAASIs. Down-titration of RAASI was independently associated with unfavorable clinical outcomes such as hospitalization and specially mortality. Although the observational nature of the study, these findings underscore the importance of preventing circumstances that may lead to RAASI down-titration, such as hyperkalemia, as well as preventing hospitalizations and mortality, to ensure RAASI benefits.
A 77-year-old Asian female with a history of left orbit exenteration and lid-sparing reconstruction for recurrent sebaceous carcinoma presented with fluid-like sensation of the left orbit. Magnetic resonance imaging (MRI) demonstrated bright T2 signal and a cyst-like cavity within the exenterated orbit. Decision was made to proceed with surgical exploration and excision. A calcified, bone-like cavity was encountered intraoperatively and removed. Histopathology revealed dense fibrous connective tissue with areas of calcification without osseous metaplasia, suggestive of retained blood in the orbit that underwent dystrophic calcification. This case report illustrates a rare occurrence of a bone-like calcific cyst following exenteration.
Procedure for obtaining feniletanolamines. Is to react 4-amino-benzaldehido with an isonitril, reducing alpha-aciloxi-acetamida obtained with a metallic hydride. Optionally, the pheniletanolamide obtained in the corresponding salt is transformed. The reaction is effected in a solvent such as tetrahydrofuran, and at temperatures that rock between 0 and 100gc, or at low temperatures: -20 to 75gc. Like hydride, boran/tetrahydrofuran is used. The reaction is effected through an aqueous base, for example, through water/ammonia. Broncolitic activity. (Machine-translation by Google Translate, not legally binding)
Clearance of HCV infection with direct-acting antivirals may lead to changes in hepatic function, which may impact the safe and effective use of concomitant medications. For example, altered blood glucose control resulting in serious symptomatic hypoglycemia has been reported in diabetic patients in postmarketing case reports and published epidemiological studies. Management of hypoglycemia in these cases required either discontinuation or dose modification of concomitant medications used for diabetes treatment. 

Frequent monitoring of relevant laboratory parameters (e.g. International Normalized Ratio [INR] in patients taking warfarin, blood glucose levels in diabetic patients) or drug concentrations of concomitant medications such as CYP P450 substrates with a narrow therapeutic index (e.g. certain immunosuppressants) is recommended to ensure safe and effective use. Dose adjustments of concomitant medications may be necessary. 

Table 6 provides the effect of MAVYRET on concentrations of coadministered drugs and the effect of coadministered drugs on glecaprevir and pibrentasvir [see Contraindications (4), Warnings and Precautions (5.3), and Clinical Pharmacology (12.3)]. All interaction studies were performed in adults.
This invention belongs to biologic medical field. It relates to a method of selecting increasing tumor cell to ionic radiation sensitivity. Artificial gene of siRNA of DNA-PK cs that doing keying action in DNA damage repairing process is made in this invention. Then function of interference DNA-PK cs gene is selected to increase sensitivity of cell to ionic radiation. At the same time, tumor selecting copy type adenovirus is used to selective increase the sensitivity of cell to ionic radiation to restrict lay curing sensitization function in tumor cell. So the normal cell and tissue near is not damaged, and the effect of curing and sensitization is reached.
Participants will receive a 6-month lifestyle weight management program based on the publicly available Prevent T2 curriculum, integrated with the Move group-based classes. Group classes will be delivered weekly in weeks 1-12, and biweekly in weeks 13-26. Group-based classes will be taught virtually by a trained Registered Dietitian. Participants will also receive a 6-month membership to the Peloton fitness app. Participants will also receive Move individualized support sessions. In addition, participants will receive access to online mental guided imagery sessions.